Laser system allows determination of atomic binding energy of the rarest element on earth

July 04, 2013

The radioactive element astatine, the name of which is derived from the Greek word for 'instability,' is so rare on earth that it has not yet been investigated to any greater extent and, as a consequence, very little is known about it. Using artificially generated astatine, the Mainz-based physicist Sebastian Rothe has now managed for the first time to experimentally explore one of its fundamental parameters, the ionization potential, and thus determine one of the most important properties of the rare element. The ionization potential is the binding energy, i.e., the amount of energy required to remove an electron from an atom's outer shell. It determines the entire chemical binding characteristics of that element. The measurements were undertaken at the laboratory of the CERN European Organization for Nuclear Research near Geneva using special lasers developed by the LARISSA working group at the Institute of Physics at Johannes Gutenberg University Mainz (JGU). The online journal Nature Communications recently published the findings.

Astatine is the rarest naturally occurring element on earth. The earth's mantel is estimated to contain only 0.07 grams. Together with fluorine, chlorine, and iodine, it is a member of the halogen group, and is formed as a result of the natural decay of uranium. Nuclear physicists now know of more than 20 isotopes which are all extremely short-lived and decay with a half-life of no more than eight hours. Alpha rays are emitted during decay, making the element particularly interesting for targeted cancer therapy thanks to its short lifespan. "Astatine is the only halogen we have known absolutely nothing about to date", explained Professor Klaus Wendt, head of the LARISSA working group at the Institute of Physics at Johannes Gutenberg University Mainz (JGU). A doctoral candidate and member of this work group, Sebastian Rothe, investigated the ionization potential of astatine using laser spectroscopy and determined it had a value of 9.31751 electron volts (eV). The measurements were conducted at CERN in Geneva and were extrapolated and confirmed at the Canadian research center for particle and nuclear physics TRIUMF in Vancouver in Canada.

LARISSA is an acronym for 'Laser Resonance Ionization for Spectroscopy in Selective Applications'. The technique is based on work originally conducted by Mainz physicist Professor Ernst Otten more than 30 years ago using the isotope mass separator ISOLDE at CERN. It is now the technique of choice employed at almost all large-scale research facilities throughout the world to produce and examine exotic radioisotopes and is commonly used applying the Mainz laser system. It involves the use of laser light for the gradual optical excitation of a valence electron of a selected atomic species until the point of ionization.

"Astatine is the last naturally occurring element whose ionization potential had yet to be determined experimentally," stated Rothe. The binding energy of the electrons in its outermost shell determines what chemical reactions astatine will undergo and thus the stability of its chemical bonds. It is believed that the astatine isotope 211 may have a major pharmaceutical potential. It is an exceptional candidate for use in cancer therapy because of its decay profile, the aggressiveness of its alpha radiation, and the limited range of its radiation. It is also a member of the halogen family, which can be readily introduced into the human body to be attached directly to cancer cells.

Sebastian Rothe et al.
Measurement of the first ionization potential of astatine by laser ionization spectroscopy
Nature Communications, May 2013
DOI: 10.1038/ncomms2819

Close-up of the Mainz laser system
photo: Pascal Naubereit
View of the Mainz laser system
photo: Pascal Naubereit

Contact and further information

Professor Dr. Klaus Wendt
Larissa work group
Institute of Physics
Johannes Gutenberg University Mainz (JGU)
D 55099 Mainz, GERMANY
phone +49 6131 39-22882
fax +49 6131 39-23428

Johannes Gutenberg Universitaet Mainz

Related Cancer Therapy Articles from Brightsurf:

Combination therapy against cancer
In their quest to destroy cancer cells, researchers are turning to combinational therapies more and more.

In one cancer therapy, two halves are safer than a whole
Splitting one type of cancer drug in half and delivering the pieces separately to cancer cells could reduce life-threatening side effects and protect healthy, non-cancerous cells, a new study suggests.

Yale Cancer Center study validates combination therapy for aggressive endometrial cancer
Yale Cancer Center (YCC) scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer.

Photodynamic therapy used to treat ovarian cancer
Photodynamic therapy (PDT) is one of the most promising methods of treating localized tumors.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

A new way to monitor cancer radiation therapy doses
More than half of all cancer patients undergo radiation therapy and the dose is critical.

Light therapy for immune cells helps with side effects of cancer therapy
A frequent side effect of cancer immunotherapies can probably be stopped by light activation of immune cells, as researchers at the Medical Center -- University of Freiburg have shown.

Residual cancer burden after neoadjuvant therapy can accurately predict breast cancer survival
Researchers from The University of Texas MD Anderson Cancer Center today reported results from a pooled analysis of more than 5,100 breast cancer patients that found residual cancer burden (RCB) continuous index and classification were independently and strongly prognostic for all breast cancer phenotypes.

Genetic diversity facilitates cancer therapy
Cancer patients with more different HLA genes respond better to treatment.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Read More: Cancer Therapy News and Cancer Therapy Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to